<DOC>
	<DOC>NCT02991131</DOC>
	<brief_summary>This open-label, prospective, multi-center, non-interventional, observational, parallel cohort study intends to provide real life data on the treatment duration, effectiveness and safety of tedizolid and linezolid when treating ABSSSI hospitalized patients in a real practice setting.</brief_summary>
	<brief_title>Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study</brief_title>
	<detailed_description>The primary objective in this study is to assess the treatment duration in the real life in the 2 cohorts consisting of patients treated by 200 mg once daily IV/ PO tedizolid or treated by 600 mg twice daily IV/PO (Intravenous/ per oral) linezolid.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Wound Infection</mesh_term>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Erysipelas</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Adult female and male inpatients with clinical diagnosis compatible with ABSSSI (cellulitis/erysipelas, major skin abscess or wound infections) with a clinical suspicion of infection by Gram positive bacteria (with or without laboratory confirmation). Patients for whom the decision to initiate treatment with tedizolid phosphate or linezolid was made as per physician's routine treatment practice. Signed informed consent. Patients participating in an investigational program with interventions outside of routine clinical practice. Patients who have been enrolled in this study before.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute bacterial skin infection</keyword>
	<keyword>Acute Bacterial Skin and Skin Structure Infection (ABSSSI)</keyword>
	<keyword>Abscess</keyword>
	<keyword>Cellulitis</keyword>
	<keyword>Erysipelas</keyword>
	<keyword>Wound infection</keyword>
	<keyword>Methicillin resistant Staphylococcus aureus (MRSA)</keyword>
</DOC>